vs

Side-by-side financial comparison of FIRST COMMUNITY CORP (FCCO) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

FIRST COMMUNITY CORP is the larger business by last-quarter revenue ($23.2M vs $19.6M, roughly 1.2× STANDARD BIOTOOLS INC.). FIRST COMMUNITY CORP runs the higher net margin — 23.7% vs -177.4%, a 201.1% gap on every dollar of revenue. Over the past eight quarters, FIRST COMMUNITY CORP's revenue compounded faster (19.1% CAGR vs -12.2%).

United Community is an American bank. United is one of the largest full-service financial institutions in the Southeast, with $27.7 billion in assets and 200 offices in Alabama, Florida, Georgia, North Carolina, South Carolina and Tennessee. In addition to its presence in the Southeast, United Community is the largest bank headquartered in South Carolina by total asset size.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

FCCO vs LAB — Head-to-Head

Bigger by revenue
FCCO
FCCO
1.2× larger
FCCO
$23.2M
$19.6M
LAB
Higher net margin
FCCO
FCCO
201.1% more per $
FCCO
23.7%
-177.4%
LAB
Faster 2-yr revenue CAGR
FCCO
FCCO
Annualised
FCCO
19.1%
-12.2%
LAB

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
FCCO
FCCO
LAB
LAB
Revenue
$23.2M
$19.6M
Net Profit
$5.5M
$-34.7M
Gross Margin
48.5%
Operating Margin
-168.5%
Net Margin
23.7%
-177.4%
Revenue YoY
-11.5%
Net Profit YoY
37.6%
-28.8%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FCCO
FCCO
LAB
LAB
Q1 26
$23.2M
Q4 25
$20.6M
Q3 25
$20.5M
$19.6M
Q2 25
$19.5M
$21.8M
Q1 25
$18.4M
$40.8M
Q4 24
$17.5M
Q3 24
$17.0M
$22.1M
Q2 24
$16.3M
$22.5M
Net Profit
FCCO
FCCO
LAB
LAB
Q1 26
$5.5M
Q4 25
Q3 25
$5.2M
$-34.7M
Q2 25
$5.2M
$-33.5M
Q1 25
$4.0M
$-26.0M
Q4 24
Q3 24
$3.9M
$-26.9M
Q2 24
$3.3M
$-45.7M
Gross Margin
FCCO
FCCO
LAB
LAB
Q1 26
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Operating Margin
FCCO
FCCO
LAB
LAB
Q1 26
Q4 25
Q3 25
32.2%
-168.5%
Q2 25
34.2%
-118.1%
Q1 25
28.2%
-80.8%
Q4 24
30.9%
Q3 24
29.5%
-120.9%
Q2 24
24.7%
-134.5%
Net Margin
FCCO
FCCO
LAB
LAB
Q1 26
23.7%
Q4 25
Q3 25
25.4%
-177.4%
Q2 25
26.6%
-153.7%
Q1 25
21.8%
-63.8%
Q4 24
Q3 24
22.7%
-122.0%
Q2 24
20.0%
-203.3%
EPS (diluted)
FCCO
FCCO
LAB
LAB
Q1 26
Q4 25
$0.62
Q3 25
$0.67
$-0.09
Q2 25
$0.67
$-0.09
Q1 25
$0.51
$-0.07
Q4 24
$0.55
Q3 24
$0.50
$-0.07
Q2 24
$0.42
$-0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FCCO
FCCO
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$220.8M
$399.7M
Total Assets
$2.4B
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FCCO
FCCO
LAB
LAB
Q1 26
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$269.8M
Total Debt
FCCO
FCCO
LAB
LAB
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Stockholders' Equity
FCCO
FCCO
LAB
LAB
Q1 26
$220.8M
Q4 25
$167.6M
Q3 25
$161.6M
$399.7M
Q2 25
$155.5M
$424.5M
Q1 25
$150.0M
$454.6M
Q4 24
$144.5M
Q3 24
$143.3M
$489.3M
Q2 24
$136.2M
$510.3M
Total Assets
FCCO
FCCO
LAB
LAB
Q1 26
$2.4B
Q4 25
$2.1B
Q3 25
$2.1B
$539.6M
Q2 25
$2.0B
$557.0M
Q1 25
$2.0B
$579.6M
Q4 24
$2.0B
Q3 24
$1.9B
$681.5M
Q2 24
$1.9B
$708.7M
Debt / Equity
FCCO
FCCO
LAB
LAB
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FCCO
FCCO
LAB
LAB
Operating Cash FlowLast quarter
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FCCO
FCCO
LAB
LAB
Q1 26
Q4 25
$18.7M
Q3 25
$9.2M
$-22.2M
Q2 25
$-236.0K
$-20.7M
Q1 25
$6.4M
$-30.3M
Q4 24
$11.6M
Q3 24
$10.8M
$-27.9M
Q2 24
$-292.0K
$-39.0M
Free Cash Flow
FCCO
FCCO
LAB
LAB
Q1 26
Q4 25
$17.6M
Q3 25
$9.0M
$-23.1M
Q2 25
$-454.0K
$-22.6M
Q1 25
$6.2M
$-35.3M
Q4 24
$10.5M
Q3 24
$10.6M
$-30.1M
Q2 24
$-634.0K
$-41.0M
FCF Margin
FCCO
FCCO
LAB
LAB
Q1 26
Q4 25
85.3%
Q3 25
44.2%
-118.1%
Q2 25
-2.3%
-103.6%
Q1 25
34.0%
-86.6%
Q4 24
60.3%
Q3 24
62.5%
-136.4%
Q2 24
-3.9%
-182.2%
Capex Intensity
FCCO
FCCO
LAB
LAB
Q1 26
Q4 25
5.4%
Q3 25
0.6%
4.5%
Q2 25
1.1%
8.7%
Q1 25
1.1%
12.4%
Q4 24
6.3%
Q3 24
1.1%
10.2%
Q2 24
2.1%
8.6%
Cash Conversion
FCCO
FCCO
LAB
LAB
Q1 26
Q4 25
Q3 25
1.77×
Q2 25
-0.05×
Q1 25
1.61×
Q4 24
Q3 24
2.80×
Q2 24
-0.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FCCO
FCCO

Net Interest Income$18.4M79%
Noninterest Income$4.8M21%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons